APEX1 and neoplasm: Compared to compound 2 (−9.23), compound 4 exhibited improved docking to the druggable pocket localized in the redox domain of APE/Ref-1; however, the MTT results showed these modifications led to a significant loss of anti-tumor activity compared to compound 2.